UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A review of GLP‐1 receptor agonists: Evolution and advancement, through the lens of randomised controlled trials

Diabetes, obesity & metabolism, 2018-02, Vol.20 (S1), p.22-33

Aroda, Vanita R.

2018

Volltextzugriff (PDF)

Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Diabetes care, 2022-11, Vol.45 (11), p.2753-2786

2022

Volltextzugriff (PDF)

2. Classification and Diagnosis of Diabetes: Standards of Care in Diabetes-2023

Diabetes care, 2023-01, Vol.46 (Suppl 1), p.S19-S40

2023

Volltextzugriff (PDF)

The Joy of Clinical Trials

Academic medicine, 2022-11, Vol.97 (11), p.1672-1672

Aroda, Vanita R

2022

Volltextzugriff (PDF)

9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2023

Diabetes care, 2023-01, Vol.46 (Suppl 1), p.S140-S157

2023

Volltextzugriff (PDF)

Coming Full Circle: Prioritizing Early Glycemic Control to Reduce Microvascular and Macrovascular Complications in People With Type 2 Diabetes

Diabetes care, 2022-04, Vol.45 (4), p.766-768

2022

Volltextzugriff (PDF)

Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial

The lancet. Diabetes & endocrinology, 2018-04, Vol.6 (4), p.275-286

2018

Volltextzugriff (PDF)

Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Diabetologia, 2022-12, Vol.65 (12), p.1925-1966

2022

Volltextzugriff (PDF)

Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial

The lancet. Diabetes & endocrinology, 2017-05, Vol.5 (5), p.355-366

2017

Volltextzugriff (PDF)

PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes

Diabetes care, 2019-09, Vol.42 (9), p.1724-1732

2019

Volltextzugriff (PDF)

Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial

Diabetes care, 2018-02, Vol.41 (2), p.258-266

2018

Volltextzugriff (PDF)

Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial

Diabetes care, 2016-11, Vol.39 (11), p.1972-1980

2016

Volltextzugriff (PDF)

11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2023

Diabetes care, 2023-01, Vol.46 (Suppl 1), p.S191-S202

2023

Volltextzugriff (PDF)

Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial

Diabetes care, 2019-12, Vol.42 (12), p.2262-2271

2019

Volltextzugriff (PDF)

8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Care in Diabetes-2023

Diabetes care, 2023-01, Vol.46 (Suppl 1), p.S128-S139

2023

Volltextzugriff (PDF)

Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors: Meta-Analysis and Systematic Review

Clinical therapeutics, 2012-06, Vol.34 (6), p.1247-1258.e22

2012

Volltextzugriff (PDF)

4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2023

Diabetes care, 2023-01, Vol.46 (Suppl 1), p.S49-s67.2

2023

Volltextzugriff (PDF)

6. Glycemic Targets: Standards of Care in Diabetes-2023

Diabetes care, 2023-01, Vol.46 (Suppl 1), p.S97-S110

2023

Volltextzugriff (PDF)

A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes

Reviews in endocrine & metabolic disorders, 2022-10, Vol.23 (5), p.979-994

2022

Volltextzugriff (PDF)

Incorporating and interpreting regulatory guidance on estimands in diabetes clinical trials: The PIONEER 1 randomized clinical trial as an example

Diabetes, obesity & metabolism, 2019-10, Vol.21 (10), p.2203-2210

2019

Volltextzugriff (PDF)

Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet (British edition), 2023-08, Vol.402 (10403), p.705-719

2023

Volltextzugriff (PDF)

Reconsidering the role of glycaemic control in cardiovascular disease risk in type 2 diabetes: A 21st century assessment

Diabetes, obesity & metabolism, 2022-12, Vol.24 (12), p.2297-2308

2022

Volltextzugriff (PDF)

10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2023

Diabetes care, 2023-01, Vol.46 (Suppl 1), p.S158-S190

2023

Volltextzugriff (PDF)

7. Diabetes Technology: Standards of Care in Diabetes-2023

Diabetes care, 2023-01, Vol.46 (Suppl 1), p.S111-S127

2023

Volltextzugriff (PDF)

GLP-1 RA and SGLT2 Inhibitors: In Harmony for Organ Protection

Journal of the American College of Cardiology, 2023-08, Vol.82 (6), p.526-528

2023

Volltextzugriff (PDF)

1 – 25 von 315

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(282)
Mit Volltextzugriff
(290)

Publikationsform

Artikel
(314)
Buchkapitel
(1)

Sprache

Englisch
(315)
Japanisch
(38)

Erscheinungsjahr

n.n

Thema

Science & Technology
(171)
Life Sciences & Biomedicine
(170)
Humans
(152)
Endocrinology & Metabolism
(130)
Diabetes
(124)
Diabetes Mellitus
(87)
Female
(69)
Male
(55)
Middle Aged
(54)
Diabetes Mellitus, Type 2 - Drug Therapy
(51)
Clinical Trials
(49)
Adult
(47)
Insulin
(47)
Type 2 Diabetes
(45)
Endocrinology
(43)
Glucose
(40)
Aged
(39)
Antidiabetics
(38)
Hypoglycemic Agents - Therapeutic Use
(38)
Standard Of Care
(37)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

A review of GLP‐1 receptor agonists: Evolution and advancement, through the lens of randomised controlled trials

Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

2. Classification and Diagnosis of Diabetes: Standards of Care in Diabetes-2023

The Joy of Clinical Trials

9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2023

Coming Full Circle: Prioritizing Early Glycemic Control to Reduce Microvascular and Macrovascular Complications in People With Type 2 Diabetes

Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial

Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial

PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes

Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial

Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial

11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2023

Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial

8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Care in Diabetes-2023

Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors: Meta-Analysis and Systematic Review

4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes-2023

6. Glycemic Targets: Standards of Care in Diabetes-2023

A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes

Incorporating and interpreting regulatory guidance on estimands in diabetes clinical trials: The PIONEER 1 randomized clinical trial as an example

Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial

Reconsidering the role of glycaemic control in cardiovascular disease risk in type 2 diabetes: A 21st century assessment

10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2023

7. Diabetes Technology: Standards of Care in Diabetes-2023

GLP-1 RA and SGLT2 Inhibitors: In Harmony for Organ Protection

Suchergebnisse filtern